France-based Bormioli Pharma announced robust growth in its North American business in 2022, with sales increasing more than 40 per cent year-over-year.

The growth in North America was matched by strong sales gains in the company’s markets worldwide, reflecting Bormioli Pharma’s multi-million dollar investments in expanding its capabilities as a provider of comprehensive packaging solutions for injectable drugs.

The US glass bottle market is dealing with continuing supply issues for injectable glass packaging as a result of the lingering effects of the COVID-19 pandemic and resulting supply chain disruptions. Bormioli Pharma is committed to providing a comprehensive solution with its ever-expanding capabilities in the area of high-value glass vials, rubber stoppers and aluminum seals.

Specifically, the company has invested in strengthening its tubular glass vials capabilities through advanced machinery, while upgrading its platform for moulded glass, and expanding clean-room capabilities for the production of rubber stoppers. These developments were supported by recent acquisitions that enable Bormioli Pharma to reliably and efficiently produce rubber and aluminum closures, as well as tubular glass vials.

“For almost 200 years, we have been leading the field of moulded glass manufacturing and now we have expanded those capabilities to tubular glass vials designed for injectable drugs and vaccines,” noted Bormioli Pharma Chief Executive Officer Andrea Lodetti. “Our proud history is matched by our current passion for innovation in the provision of innovative comprehensive packaging solutions for drug makers. As a single supplier of all the components of the injection drug kit, we can offer a wide variety of cost-effective, flexible solutions tailored to the customer’s needs, while also pursuing an ambitious agenda to greatly increase the sustainability of all our operations. Our multifaceted commitments are driven by two major factors – the supply chain issues from the continuing shortage of glass packaging for injectable drugs and the stark reminders of the inescapable dangers of ongoing climate change.”

In anticipation of its upcoming 200th anniversary, Bormioli Pharma launched “50-in-5,” an ambitious programme to achieve 50 per cent of sustainable raw materials in its pharmaceutical packaging production by 2025. “50-in-5” is a project impacting the entire manufacturing footprint. To achieve this ambitious goal, the company has been strengthening and expanding its industrial platform, with investments of more than 50 million euros to date that will be matched by similar investments over the next three years. Strategies include increasing the percentage of recycled materials throughout the production process and adopting carbon capture and other green materials for container closure components and seals.